Exclusive Summary

• - Fully off‑patent glycopeptide injection; 200/400 mg SKUs align with global dosing and hospital tender norms for fast market entry.
• - Addresses sustained IV anti‑MRSA demand (MRSA proportions around 40% or higher in many countries) with lower nephrotoxicity and OPAT suitability.
• - Strong value vs vancomycin and premium anti‑MRSA agents, typically delivering 30–60% savings in tenders.
• - Lyophilized, ambient‑storage format and mature registration pathways de‑risk multi‑country distribution.
• - Not FDA‑approved, so focus on Europe/Asia/Latin America/MENA hospital channels where competition is more manageable.